Preclinical childhood sarcoma models: Drug efficacy biomarker identification and validation

Brian Geier, Dias Kurmashev, Raushan T. Kurmasheva, Peter J. Houghton

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and "omics" approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.

Original languageEnglish (US)
Article number193
JournalFrontiers in Oncology
Issue numberAug
StatePublished - 2015


  • Bioinformatics
  • Biomarkers
  • Copy number variation
  • Drug efficacy
  • Drug sensitivity
  • Expression profiling
  • Human tumor xenografts
  • Preclinical pharmacology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Preclinical childhood sarcoma models: Drug efficacy biomarker identification and validation'. Together they form a unique fingerprint.

Cite this